Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
Three-Dimensional Approach for Modeling Nasal Mucociliary Clearance via Computational Fluid Dynamics (CFD) (U01)
The nasal mucosa offers an effective target for inhaled drugs that either treat localized nasal conditions or quickly deliver drugs to the systemic circulation [1–3].
While nasal spray drug product designs can vary considerably between innovators, most sprays are formulated as either a homogeneous
solution or a heterogeneous suspension; in the latter case, solid drug particles are dispersed within a carrier liquid [4].
Despite the many advancements in nasal drug delivery, effectively administering drugs via this route still poses many challenges.
One of the main challenges relates to mucociliary motion, which tends to transport and clear drug particles from the nasal cavity after deposition, limiting the available time for drug absorption at the intended site of action [5-8].
Many previous nasal spray models have considered solution formulations, where the active drug is already dissolved into a carrier liquid [9-11].
These computational fluid dynamics (CFD) models of nasal spray transport are currently well-developed and show good agreement with in vitro depositional data, but stop at the point of droplet deposition [12-19].
When considering a suspension-type formulation, an accurate model requires simulations of spray droplet transport along with the dissolution of the suspended drug particles in the nasal mucus, during which time mucociliary clearance is occurring.
In cases where inhaled particles are either very large or insoluble in mucus, insufficient dissolution may result in reduced drug delivery to the nasal epithelium, reducing the overall effectiveness of the drug product [1,2,20,21].
A recently developed model demonstrates the effects of mucociliary clearance on drug absorption from a suspension formulation [22].
However, this model only considered a flattened surface representation of the nasal cavity, and was therefore unable to show uptake in specific nasal regions (e.g., the olfactory region).
To study targeted nasal therapies, it is desirable to model drug uptake in an anatomically-realistic, three-dimensional model.
Finally, the effects of interindividual variability on nasal drug delivery and clearance have not been fully quantified.
Studies have shown that differences in individual nasal geometry can have a large impact on airflow patterns [26], but the full extent of mucus properties, impaired mucociliary function, or general inflammatory disease states on drug delivery have not been completely explored.
Because many nasal spray drug products are used to treat medical conditions that cause variations from a "healthy" state, it is important to quantify how these various factors may influence the overall efficacy of nasal sprays.
Objectives The objective is to study the three-dimensional effects of mucociliary clearance on localized drug absorption in respiratory airways, particularly the nasal cavity, utilizing a computational modeling approach.
The model should be adaptable to cases of intersubject variability, which may include variations in mucociliary clearance rates, changes in nasal geometry, and the presence of relevant disease states (e.g., nasal inflammation, changes in mucus properties, etc.).
The desired outcome is a computational methodology that predicts regional absorption of inhaled drugs, particularly those whose formulations include solid or suspended drug particles and may target specific nasal regions.
Detailed Description A computational modeling approach will be developed to study the effects of nasal mucociliary clearance on inhaled drug absorption and the changes that result from differences in drug formulation, disease states, and interindividual anatomical differences.
The model should consider realistic three-dimensional nasal airway geometries and account for device effects, inhalation, particle/droplet deposition, and, importantly, drug dissolution and absorption at the epithelium.
The approach should provide a direct interface between the mucociliary clearance model and CFD simulations of spray deposition.
The physiological model should consider the entire nasal airway from the nostril to the throat; variations to the geometry, representative of interindividual differences, should also be considered.
The mucociliary clearance model should be general enough to allow for changes in mucus properties and clearance rates based on healthy and disease states.
A straight-forward approach would utilize CFD simulations of inhalation and spray/particle transport to provide regional deposition data, while the three-dimensional mucociliary clearance model would demonstrate localized drug absorption and indicate the efficacy of drug products that target specific nasal regions.
Since the development of the methodology for creating the three-dimensional CFD mucociliary clearance model is considered a primary outcome of this research, it is expected that the methodology would be made available to the FDA and preferably to the public as well in such a way that it may be reproduced, either through detailed publication of the methodology and/or through sharing of codes, models, etc.
Validation of the CFD simulations with in vitro or in vivo data should be included, which should demonstrate similarity between predicted local mucociliary clearance and in vivo clearance of drug particles.
If possible, it is preferable that the model be validated against multiple drug products.
All relevant physics should be considered in the model; these physics may include (but are not limited to) spray turbulence, Lagrangian droplet/particle transport, mucus properties, mucociliary clearance, particle dissolution, and drug partitioning between the mucus and nasal epithelium.
The proposal can include specific drug products to be studied; however, after award, the selection of drug products will be revisited in a collaborative discussion with the FDA.
Suspension formulations or insufflation studies would be encouraged.
The study should consist of four phases:
Phase 1:
Selection, identification, and construction of physiological models and inhalation patterns that will best characterize interindividual variability.
Phase 2:
Development and validation of the computational fluid dynamics model and mucociliary clearance model.
Phase 3:
Performance of simulations and post-processing of simulation data.
Phase 4:
Overall assessment of the relationship between drug product formulation, mucociliary clearance, interindividual variability, and regional drug absorption.
Phase 5:
Preparation of manuscripts, which is intended to be done in the third year of the grant, and is the reason for the reduced budget for that year.
This phase may also begin earlier than the third year.
References [1] HR Costantino, L Illum, G Brandt, PH Johnson, and SC Quay:
Intranasal delivery:
Physicochemical and therapeutic aspects.
Intl J Pharma.
2007;337:1–2 4. [2] AA Hussain:
Intranasal drug delivery.
Adv Drug Deliv Rev.
1998;29:39–4 9. [3] S Turker, E Onur, and Y Ozer:
Nasal route and drug delivery systems.
Pharma World Sci.
2004;26:137–14 2. [4] SA Shah, RL Berger, J McDermott, P Gupta, D Monteith, A Connor, and W Lin:
Regional deposition of mometasone furoate nasal spray suspension in humans.
Allergy Asthma Proc.
2015;36:48–5 7. [5] FA Fry, and A Black:
Regional deposition and clearance of particles in the human nose.
J Aerosol Sci.
1973;4:113–12 4. [6] DF Proctor, and G Lundqvist:
Clearance of inhaled particles from the human nose.
Arch Int Med.
1973;131:132–13 9. [7] NGM Schipper, JC Verhoef, and FWHM Merkus:
The nasal mucociliary clearance:
Relevance to nasal drug delivery.
Pharm Res.
1991;8:807–81 4. [8] AG Beule:
Physiology and pathophysiology of the paranasal sinuses.
GMS Curr Topics Otorhinolaryngol Head Neck Surg.
2010; 9. [9] JD Suman, BL Laube, and R Dalby:
Comparison of nasal deposition and clearance of aerosol generated by a nebulizer and an aqueous spray pump.
Pharma Res.
1999;16:1648–165 2. [10] J Hardy, S Lee, and C Wilson:
Intranasal drug delivery by spray and drops.
J Pharmacy Pharmacol.
1985;37:294–29 7. [11] PG Djupesland, A Skretting, M Winderen, and T Holand:
Breath actuated device improves delivery to target sites beyond the nasal valve.
Laryngoscope.
2006;116:466–47 2. [12] Y Liu, EA Matida, and MR Johnson:
Experimental measurements and computational modeling of aerosol deposition in the Carleton-Civic standardized human nasal cavity.
J Aerosol Sci.
2010;41:569–58 6. [13] K Inthavong, Q Ge, CMK Se, W Yang, and JY Tu:
Simulation of sprayed particle feposition in a human nasal cavity including a nasal spray device.
J Aerosol Sci.
2011;42:100–11 3. [14] JD Schroeter, JS Kimbell, and B Asgharian:
Analysis of particle deposition in the turbinate and olfactory regions using a human nasal computational fluid dynamics model.
J Aerosol Med.
2006;19:301–31 3. [15] H Shi, C Kleinstreuer, and Z Zhang:
Modeling of inertial particle transport and deposition in human nasal cavities with wall roughness.
J Aerosol Sci.
2007;38:398–41 9. [16] JD Schroeter, GJM Garcia, and JS Kimbell:
Effects of surface smoothness on inertial particle deposition in human nasal models.
J Aerosol Sci.
2011;42:52–6 3. [17] J Xi, X Si, JW Kim, and A Berlinski:
Simulation of airflow and aerosol deposition in the nasal cavity of a 5-year-old child.
J Aerosol Sci.
2011;42:156–17 3. [18] SM Wang, K Inthavong, J Wen, JY Tu, and CL Xue:
Comparison of micron- and nanoparticle deposition patterns in a realistic human nasal cavity.
Resp Physiol Neurobiol.
2009;166:142–15 1. [19] JS Kimbell, RA Segal, B Asgharian, BA Wong, JD Schroeter, JP Southall, CJ Dickens, G Brace, and FJ Miller:
Characterization of deposition from nasal spray devices using a computational fluid dynamics model of the human nasal passages.
J Aerosol Med.
2007;20:59–7 4. [20] P Arora, S Sharma, and S Garg:
Permeability issues in nasal drug delivery.
Drug Discov Today.
2002;7:967–97 5. [21] L Illum:
Nasal drug delivery:
New developments and strategies.
Drug Discov Today.
2002;7:1184–118 9. [22] Rygg Alex and Longest P.
Worth:
Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose:
Development of a CFD Model.
Journal of Aerosol Medicine and Pulmonary Drug Delivery.
2016;29(5):416-43 1. [26] Zhao, Kai and Scherer, Peter W and Hajiloo, Shoreh A and Dalton, Pamela.
Effect of Anatomy on Human Nasal Air Flow and Odorant Transport Patterns:
Implications for Olfaction.
Chemical Senses.
2004;29(5):365-37 9.
While nasal spray drug product designs can vary considerably between innovators, most sprays are formulated as either a homogeneous
solution or a heterogeneous suspension; in the latter case, solid drug particles are dispersed within a carrier liquid [4].
Despite the many advancements in nasal drug delivery, effectively administering drugs via this route still poses many challenges.
One of the main challenges relates to mucociliary motion, which tends to transport and clear drug particles from the nasal cavity after deposition, limiting the available time for drug absorption at the intended site of action [5-8].
Many previous nasal spray models have considered solution formulations, where the active drug is already dissolved into a carrier liquid [9-11].
These computational fluid dynamics (CFD) models of nasal spray transport are currently well-developed and show good agreement with in vitro depositional data, but stop at the point of droplet deposition [12-19].
When considering a suspension-type formulation, an accurate model requires simulations of spray droplet transport along with the dissolution of the suspended drug particles in the nasal mucus, during which time mucociliary clearance is occurring.
In cases where inhaled particles are either very large or insoluble in mucus, insufficient dissolution may result in reduced drug delivery to the nasal epithelium, reducing the overall effectiveness of the drug product [1,2,20,21].
A recently developed model demonstrates the effects of mucociliary clearance on drug absorption from a suspension formulation [22].
However, this model only considered a flattened surface representation of the nasal cavity, and was therefore unable to show uptake in specific nasal regions (e.g., the olfactory region).
To study targeted nasal therapies, it is desirable to model drug uptake in an anatomically-realistic, three-dimensional model.
Finally, the effects of interindividual variability on nasal drug delivery and clearance have not been fully quantified.
Studies have shown that differences in individual nasal geometry can have a large impact on airflow patterns [26], but the full extent of mucus properties, impaired mucociliary function, or general inflammatory disease states on drug delivery have not been completely explored.
Because many nasal spray drug products are used to treat medical conditions that cause variations from a "healthy" state, it is important to quantify how these various factors may influence the overall efficacy of nasal sprays.
Objectives The objective is to study the three-dimensional effects of mucociliary clearance on localized drug absorption in respiratory airways, particularly the nasal cavity, utilizing a computational modeling approach.
The model should be adaptable to cases of intersubject variability, which may include variations in mucociliary clearance rates, changes in nasal geometry, and the presence of relevant disease states (e.g., nasal inflammation, changes in mucus properties, etc.).
The desired outcome is a computational methodology that predicts regional absorption of inhaled drugs, particularly those whose formulations include solid or suspended drug particles and may target specific nasal regions.
Detailed Description A computational modeling approach will be developed to study the effects of nasal mucociliary clearance on inhaled drug absorption and the changes that result from differences in drug formulation, disease states, and interindividual anatomical differences.
The model should consider realistic three-dimensional nasal airway geometries and account for device effects, inhalation, particle/droplet deposition, and, importantly, drug dissolution and absorption at the epithelium.
The approach should provide a direct interface between the mucociliary clearance model and CFD simulations of spray deposition.
The physiological model should consider the entire nasal airway from the nostril to the throat; variations to the geometry, representative of interindividual differences, should also be considered.
The mucociliary clearance model should be general enough to allow for changes in mucus properties and clearance rates based on healthy and disease states.
A straight-forward approach would utilize CFD simulations of inhalation and spray/particle transport to provide regional deposition data, while the three-dimensional mucociliary clearance model would demonstrate localized drug absorption and indicate the efficacy of drug products that target specific nasal regions.
Since the development of the methodology for creating the three-dimensional CFD mucociliary clearance model is considered a primary outcome of this research, it is expected that the methodology would be made available to the FDA and preferably to the public as well in such a way that it may be reproduced, either through detailed publication of the methodology and/or through sharing of codes, models, etc.
Validation of the CFD simulations with in vitro or in vivo data should be included, which should demonstrate similarity between predicted local mucociliary clearance and in vivo clearance of drug particles.
If possible, it is preferable that the model be validated against multiple drug products.
All relevant physics should be considered in the model; these physics may include (but are not limited to) spray turbulence, Lagrangian droplet/particle transport, mucus properties, mucociliary clearance, particle dissolution, and drug partitioning between the mucus and nasal epithelium.
The proposal can include specific drug products to be studied; however, after award, the selection of drug products will be revisited in a collaborative discussion with the FDA.
Suspension formulations or insufflation studies would be encouraged.
The study should consist of four phases:
Phase 1:
Selection, identification, and construction of physiological models and inhalation patterns that will best characterize interindividual variability.
Phase 2:
Development and validation of the computational fluid dynamics model and mucociliary clearance model.
Phase 3:
Performance of simulations and post-processing of simulation data.
Phase 4:
Overall assessment of the relationship between drug product formulation, mucociliary clearance, interindividual variability, and regional drug absorption.
Phase 5:
Preparation of manuscripts, which is intended to be done in the third year of the grant, and is the reason for the reduced budget for that year.
This phase may also begin earlier than the third year.
References [1] HR Costantino, L Illum, G Brandt, PH Johnson, and SC Quay:
Intranasal delivery:
Physicochemical and therapeutic aspects.
Intl J Pharma.
2007;337:1–2 4. [2] AA Hussain:
Intranasal drug delivery.
Adv Drug Deliv Rev.
1998;29:39–4 9. [3] S Turker, E Onur, and Y Ozer:
Nasal route and drug delivery systems.
Pharma World Sci.
2004;26:137–14 2. [4] SA Shah, RL Berger, J McDermott, P Gupta, D Monteith, A Connor, and W Lin:
Regional deposition of mometasone furoate nasal spray suspension in humans.
Allergy Asthma Proc.
2015;36:48–5 7. [5] FA Fry, and A Black:
Regional deposition and clearance of particles in the human nose.
J Aerosol Sci.
1973;4:113–12 4. [6] DF Proctor, and G Lundqvist:
Clearance of inhaled particles from the human nose.
Arch Int Med.
1973;131:132–13 9. [7] NGM Schipper, JC Verhoef, and FWHM Merkus:
The nasal mucociliary clearance:
Relevance to nasal drug delivery.
Pharm Res.
1991;8:807–81 4. [8] AG Beule:
Physiology and pathophysiology of the paranasal sinuses.
GMS Curr Topics Otorhinolaryngol Head Neck Surg.
2010; 9. [9] JD Suman, BL Laube, and R Dalby:
Comparison of nasal deposition and clearance of aerosol generated by a nebulizer and an aqueous spray pump.
Pharma Res.
1999;16:1648–165 2. [10] J Hardy, S Lee, and C Wilson:
Intranasal drug delivery by spray and drops.
J Pharmacy Pharmacol.
1985;37:294–29 7. [11] PG Djupesland, A Skretting, M Winderen, and T Holand:
Breath actuated device improves delivery to target sites beyond the nasal valve.
Laryngoscope.
2006;116:466–47 2. [12] Y Liu, EA Matida, and MR Johnson:
Experimental measurements and computational modeling of aerosol deposition in the Carleton-Civic standardized human nasal cavity.
J Aerosol Sci.
2010;41:569–58 6. [13] K Inthavong, Q Ge, CMK Se, W Yang, and JY Tu:
Simulation of sprayed particle feposition in a human nasal cavity including a nasal spray device.
J Aerosol Sci.
2011;42:100–11 3. [14] JD Schroeter, JS Kimbell, and B Asgharian:
Analysis of particle deposition in the turbinate and olfactory regions using a human nasal computational fluid dynamics model.
J Aerosol Med.
2006;19:301–31 3. [15] H Shi, C Kleinstreuer, and Z Zhang:
Modeling of inertial particle transport and deposition in human nasal cavities with wall roughness.
J Aerosol Sci.
2007;38:398–41 9. [16] JD Schroeter, GJM Garcia, and JS Kimbell:
Effects of surface smoothness on inertial particle deposition in human nasal models.
J Aerosol Sci.
2011;42:52–6 3. [17] J Xi, X Si, JW Kim, and A Berlinski:
Simulation of airflow and aerosol deposition in the nasal cavity of a 5-year-old child.
J Aerosol Sci.
2011;42:156–17 3. [18] SM Wang, K Inthavong, J Wen, JY Tu, and CL Xue:
Comparison of micron- and nanoparticle deposition patterns in a realistic human nasal cavity.
Resp Physiol Neurobiol.
2009;166:142–15 1. [19] JS Kimbell, RA Segal, B Asgharian, BA Wong, JD Schroeter, JP Southall, CJ Dickens, G Brace, and FJ Miller:
Characterization of deposition from nasal spray devices using a computational fluid dynamics model of the human nasal passages.
J Aerosol Med.
2007;20:59–7 4. [20] P Arora, S Sharma, and S Garg:
Permeability issues in nasal drug delivery.
Drug Discov Today.
2002;7:967–97 5. [21] L Illum:
Nasal drug delivery:
New developments and strategies.
Drug Discov Today.
2002;7:1184–118 9. [22] Rygg Alex and Longest P.
Worth:
Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose:
Development of a CFD Model.
Journal of Aerosol Medicine and Pulmonary Drug Delivery.
2016;29(5):416-43 1. [26] Zhao, Kai and Scherer, Peter W and Hajiloo, Shoreh A and Dalton, Pamela.
Effect of Anatomy on Human Nasal Air Flow and Odorant Transport Patterns:
Implications for Olfaction.
Chemical Senses.
2004;29(5):365-37 9.
Agency: Department of Health and Human Services
Office: Food and Drug Administration
Estimated Funding: $280,000
Office: Food and Drug Administration
Estimated Funding: $280,000
Who's Eligible
Obtain Full Opportunity Text:
DARPA-BAA-11-66
Additional Information of Eligibility:
Please see full announcement.
Full Opportunity Web Address:
https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-18-020.html
Contact:
Agency Email Description:
Shashi.Malhotra@fda.hhs.gov
Agency Email:
Date Posted:
2018-03-22
Application Due Date:
Archive Date:
2018-07-04
Social Entrepreneurship
Spotlight
A Bar That Saves Children’s Lives
Ryan Devlin, Todd Grinnell and Ravi Patel have traveled to Africa on a humanitarian trip a few years back, encountering children suffering from severe malnutrition get healthy through Plumpy’Nut®.
Learn How to Identify and Avoid Grant Scams
